---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046034"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:39:10.686154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M

## Summary
- Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales in Q3.
- Net loss $5.4M ($0.24/share) vs $4.0M ($0.26/share) in Q3 2023.
- Cash $7.6M; expects runway into July 2025.
- Announced partnerships with Boston IVF and Spain distributors; Spain deals expected >$1.3M over next year.
- Received FDA clearance for FemChec, CE mark for FemVue MINI, and patent for FemBloc.

## SEC filing metadata
- accession: 0001140361-24-046034
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036124046034/0001140361-24-046034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036124046034/ef20038399_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046034
- JSON: https://secwatch.observer/filing/0001140361-24-046034.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.